Storm forecasting: Additional lessons from the CD28 superagonist TGN1412 trial

Nature Reviews Immunology

Volumn 12, Issue 10, 2012, Pages 740-

  Horvath, Christopher ^a   Andrews, Laura ^b   Baumann, Andreas ^c   Black, Lauren ^d   Blanset, Diann ^e   Cavagnaro, Joy ^f   Hastings, Kenneth L ^g   Hutto, David L ^h   MacLachlan, Timothy K ⁱ   Milton, Mark ⁱ   Reynolds, Theresa ^j   Roberts, Stan ^k   Rogge, Mark ^l   Sims, Jennifer ^m   Treacy, George ⁿ   Warner, Garvin ^o   Green, James D ^e  

^a INTICA Biomedical   (United States)

^b Genzyme   (United States)

^c BAYER PHARMA AG   (Germany)

^d CHARLES RIVER LABORATORIES   (United States)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f Access BIO   (United States)

^g Sanofi SA   (United States)

^h EISAI INC   (United States)

ⁱ Novartis   (United States)

^j GENENTECH INC   (United States)

^k SAR Safety Assessment   (United States)

^l BIOGEN   (United States)

^m Integrated Biologix GmbH   (Switzerland)

ⁿ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^o ALNYLAM PHARMACEUTICALS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; JJ 316; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 3; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; TGN 1412; UNCLASSIFIED DRUG; VISILIZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG TARGETING; HAPLORHINI; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LETTER; LYMPHOCYTE COUNT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; REGULATORY T LYMPHOCYTE; SEPTIC SHOCK; SEX DIFFERENCE; SINGLE DRUG DOSE; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; THYMOCYTE; TREATMENT OUTCOME; ERRATUM; ERROR;

EID: 84866740431     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3302     Document Type: Letter

References (16)

1. Hünig, T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nature Rev. Immunol. 12, 317-318 (2012).
2. Proft, T. & Fraser, J. D. Bacterial superantigens. Clin. Exp. Immunol. 133, 299-306 (2003).
3. Horvath, C. J. & Milton, M. N. The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event? Toxicol. Pathol. 37, 372-383 (2009).
4. Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
5. Medicines and Healthcare Products Regulatory Agency. Clinical trial suspension: latest findings. MHRA [online], http://www.mhra.gov.uk/NewsCentre/ Pressreleases/CON2023515 (2006).
6. Lühder, F. et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med. 197, 955-966 (2003).
7. Tacke, M., Hanke, G., Hanke, T. & Hünig, T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur. J. Immunol. 27, 239-247 (1997).
8. Lin, C. H. & Hünig, T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. J. Immunol. 33, 626-638 (2003).
9. Stebbings, R. et al. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 179, 3325-3331 (2007).
10. -/-mice. Blood 108, 238-245 (2006).
11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline S6: preclinical safety evaluation of biotechnology-derived pharmaceuticals (ICH, 1997).
12. US Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers (FDA, 2005).
13. Association of the British Pharmaceutical Industry/BioIndustry Association. Guideline for preclinical and clinical testing of new medicinal products. Parts 1 & 2 (ABPI, 1977).
14. Sims, J. & ABPI/BIA Early Stage Clinical Trials Task Force. Calculation of the minimum anticipated biological effect level (MABEL) and 1st dose in humans. EMA [online], http://www.ema.europa.eu/docs/en-GB/document- library/Presentation/2009/11/WC500010862.pdf (2007).
15. Lowe, P. J. et al. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica 37, 1331-1354 (2007).
16. Lowe, P. J., Tannenbaum, S., Wu, K., Lloyd, P. & Sims, J. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin. Pharmacol. Toxicol. 106, 195-209 (2010).